StockData
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. (BCAX) stock

BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.60−0.15 (-1.54%)

Close on Nov 17, 2026Market cap $635.26MP/E –Yield –

Bicara Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Bicara Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$161.73M. For fiscal 2025 it was -$106.83M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$106.83M–
FY2024Dec 31, 2024-$74.75M–
FY2023Dec 31, 2023-$45.63M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$56.13M–
Q2 FY2026Jun 30, 2026-$44.21M–
Q1 FY2026Mar 31, 2026-$37.51M–
Q4 FY2025Dec 31, 2025-$23.89M–
Q3 FY2025Sep 30, 2025-$29.25M–
Q2 FY2025Jun 30, 2025-$25.59M–
Q1 FY2025Mar 31, 2025-$28.11M–
Q4 FY2024Dec 31, 2024-$30.03M–
Q3 FY2024Sep 30, 2024-$17.22M–
Q2 FY2024Jun 30, 2024-$12.91M–
Q1 FY2024Mar 31, 2024-$14.59M–
Q4 FY2023Dec 31, 2023-$8.04M–

More Bicara Therapeutics figures

See a number that looks wrong?